When was Eisai founded?

Eisai was founded in 1941 and raised its 1st funding round 66 years after it was founded.

Where is Eisai located?

Eisai is headquartered in Jakarta, Indonesia. It is registered at 93/1 ยูนิต 603-604, 6 จีพีเอฟ วิทยุ ทาวเวอร์ เอ, วิทยุ, ลุมพินี, เขตปทุมวัน, กรุงเทพมหานคร.

How many employees does Eisai have?

As of Dec 06, 2025, the latest employee count at Eisai is 2813.

Is Eisai a funded company?

Eisai is a funded company, having raised an undisclosed amount across 3 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Aug 15, 2007.

When was the latest funding round of Eisai?

Eisai's latest funding was a $***** Grant (prize money) round on Jan 28, 2025, with participation from 1 investor.

Where does Eisai rank among its competitors?

Eisai ranks 20th amongst 1163 active competitors, of which 64 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Johnson & Johnson, which secured $34M in Feb, 2025.

Who are the top competitors of Eisai?

Eisai's top competitors include Amgen, Merck and AbbVie. Among them, Johnson & Johnson secured the most recent funding round in February, 2025.

Eisai - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of drugs for oncology and neurological disorders. The company's products include ciphex/Pariet (rabeprazole) for Gastroesophageal reflux disease, Actonel (risedronic acid) for Osteoporosis, Aloxi (palonosetron) for Chemotherapy-induced nausea and vomiting, Aricept (donepezil) for Alzheimer's Disease, Banzel/Inovelon (rufinamide) for seizures related to Lennox for gastaut syndrome, Belviq (lorcaserin) for obesity, Fragmin (dalteparin) for deep vein thrombosis and pulmonary embolism, and more.

Website: www.eisai.com/index.html
Social
Phone Number: +81 **********
Registered Address: 93/1 ยูนิต 603-604, 6 จีพีเอฟ วิทยุ ทาวเวอร์ เอ, วิทยุ, ลุมพินี, เขตปทุมวัน, กรุงเทพมหานคร

Key Metrics

Founded Year

1941

Location

Jakarta, Indonesia

Stage

Public

Latest Funding Round

Grant (prize money), Jan 28, 2025, $*****

Investors

Petrillo Capital & 3 more

Ranked

20^th among 1163 active competitors

Employee Count

2,813 as on Dec 06, 2025

Investment & Acquisitions

Seed Therapeutics & 10 more

Similar Companies

Amgen & 1187 more

Exit Details

Public

View Eisai's full profile

Eisai is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
EISAI (THAILAND) MARKETING CIN: 0105532098891 , Thailand, Active	Oct 17, 1989	$77.4M (As on Dec 31, 2023)	-

Eisai got listed on Sep 14, 1961.

Click here to take a look at Eisai's IPO in detail

Eisai has raised funding over 3 rounds. Its first funding round was on Aug 15, 2007. Its latest funding round was a Grant (prize money) round on Jan 28, 2025 for $*****. 1 investor participated in its latest round. Eisai has 4 institutional investors.

Here is the list of recent funding rounds of Eisai:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 28, 2025	5297925	Grant (prize money)	7000402	5605451	8414670	2140668
Mar 01, 2011	2344344	Grant (prize money)	5749469	6933983	8305291	HHS
Aug 15, 2007	7761002	Grant (prize money)	2894168	4266477	9083870	HHS

Access funding benchmarks and valuations. Sign up today!

View details of Eisai's funding rounds and investors

Eisai's employee count trend

Eisai has 2,813 employees as of Dec 25. Here is Eisai's employee count trend over the years:

Uncover Eisai's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Eisai include Amgen, Merck and AbbVie. Here is the list of Top 10 competitors of Eisai, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Amgen 1980, Thousand Oaks (United States), Public	Developer of pharmaceutical products for treating multiple diseases	-	Digital Pharma Lab, Amgen Business Development ... & 11 others	82/100
2nd	Merck 1891, Kenilworth (United Kingdom), Public	Manufacturer of pharmaceutical products	-	Bill & Melinda Gates Foundation, Berkshire Hathaway ... & 11 others	82/100
3rd	AbbVie 2012, Chicago (United States), Public	Research-based biopharmaceutical company	$14.7B	Berkshire Hathaway, Alcor Fund & 8 others	81/100
4th	Gilead 1987, Foster City (United States), Public	Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others	-	Aisling Capital, BB Biotech & 17 others	80/100
5th	Lilly 1876, Indianapolis (United States), Public	Developer of traditional pharmaceutical medicines	-	Alcor Fund, Digital Pharma Lab & 11 others	80/100
6th	Johnson & Johnson 1886, New Brunswick (United States), Public	Manufacturer and supplier of beauty care products, medical devices, and pharmaceutical products	-	Alcor Fund, 27th Street Capital & 16 others	78/100
7th	Pfizer 1849, New York City (United States), Public	Provider of pharmaceutical products for multiple disease treatments	-	Berkshire Hathaway, Alcor Fund & 16 others	73/100
8th	Roivant Sciences 2014, New York City (United States), Public	Developer of therapeutics to treat neurology, oncology, rare, and endocrinology based diseases	$1.3B	SoftBank Vision Fund, NovaQuest Capital Management ... & 7 others	71/100
9th	Novartis 1996, Basel (Switzerland), Public	R&D focused on manufacturing of drugs for multiple therapeutic areas	-	Digital Pharma Lab, New Enterprise Associates ... & 9 others	70/100
10th	United Therapeutics 1998, Silver Spring (United States), Public	Specialty company developing treatment for chronic and life-threatening diseases	-	Tekla Capital Management, International Biotechnology Trust ... & 4 others	69/100
20th	Eisai 1941, Jakarta (Indonesia), Public	Developer of drugs for oncology and neurological disorders	-	Petrillo Capital, Plexus Ventures & 2 others	67/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Eisai's competitors? Click here to see the top ones

Eisai has made 8 investments in companies including Seed Therapeutics and Seed Therapeutics. Eisai has also acquired 3 companies including AkaRx and MGI Pharma.

Here is the list of investments & acquisitions:

Filter this list

Date of Investment/Acquisition	Type	Company Name	Founded Year	Location
Aug 2025	Investments	Seed Therapeutics	2019	New York City (United States)
Aug 2024	Investments	Seed Therapeutics	2019	New York City (United States)
Mar 08, 2024	Investments	RecoMed	2013	Cape Town (South Africa)